The state-of-play and future of antibody therapeutics
Z Elgundi, M Reslan, E Cruz, V Sifniotis… - Advanced drug delivery …, 2017 - Elsevier
It has been over four decades since the development of monoclonal antibodies (mAbs)
using a hybridoma cell line was first reported. Since then more than thirty therapeutic …
using a hybridoma cell line was first reported. Since then more than thirty therapeutic …
[HTML][HTML] Exploring alternative antibody scaffolds: Antibody fragments and antibody mimics for targeted drug delivery
DA Richards - Drug Discovery Today: Technologies, 2018 - Elsevier
The field of targeted therapeutics has benefitted immeasurably from the development of high-
affinity antibodies. These important ligands have facilitated the development of effective …
affinity antibodies. These important ligands have facilitated the development of effective …
Therapeutic antibodies: market considerations, disease targets and bioprocessing
JG Elvin, RG Couston, CF Van Der Walle - International journal of …, 2013 - Elsevier
Antibodies are well established in mainstream clinical practice and present an exciting area
for collaborative research and development in industry and academia alike. In this review …
for collaborative research and development in industry and academia alike. In this review …
Next generation antibody drugs: pursuit of the'high-hanging fruit'
PJ Carter, GA Lazar - Nature Reviews Drug Discovery, 2018 - nature.com
Antibodies are the most rapidly growing drug class and have a major impact on human
health, particularly in oncology, autoimmunity and chronic inflammatory diseases. Many of …
health, particularly in oncology, autoimmunity and chronic inflammatory diseases. Many of …
Biosimilar, biobetter and next generation therapeutic antibodies
A Beck - MAbs, 2011 - Taylor & Francis
Correspondence to: Alain Beck; Email: alain. beck@ pierre-fabre. com Submitted: 01/11/10;
Accepted: 01/11/11 DOI: 10.4161/mabs. 3.2. 14785 in a sometimes confusing way. 4 To …
Accepted: 01/11/11 DOI: 10.4161/mabs. 3.2. 14785 in a sometimes confusing way. 4 To …
Formulation and delivery issues for monoclonal antibody therapeutics
AL Daugherty, RJ Mrsny - Advanced drug delivery reviews, 2006 - Elsevier
Antibodies can have exquisite specificity of target recognition and thus generate highly
selective outcomes following their systemic administration. While antibodies can have high …
selective outcomes following their systemic administration. While antibodies can have high …
The dawn of a new era: targeting the “undruggables” with antibody-based therapeutics
The high selectivity and affinity of antibodies toward their antigens have made them a highly
valuable tool in disease therapy, diagnosis, and basic research. A plethora of chemical and …
valuable tool in disease therapy, diagnosis, and basic research. A plethora of chemical and …
Tailor-made antibody therapeutics
PS Chowdhury, H Wu - Methods, 2005 - Elsevier
Therapeutic antibodies represent one of the fastest growing areas of the pharmaceutical
industry. There are currently 18 monoclonal antibodies in the market that have been …
industry. There are currently 18 monoclonal antibodies in the market that have been …
[HTML][HTML] Clinical considerations for biosimilar antibodies
H Mellstedt - European Journal of Cancer Supplements, 2013 - Elsevier
Biosimilar agents are approximate copies of branded biologic therapies. Since the first
biosimilar was authorized in the European Union in 2006, fifteen additional agents have …
biosimilar was authorized in the European Union in 2006, fifteen additional agents have …
Antibodies and associates: Partners in targeted drug delivery
PJ Kennedy, C Oliveira, PL Granja… - Pharmacology & …, 2017 - Elsevier
Monoclonal antibodies (mAbs) are well established in the clinic due to their specificity and
affinity to a diverse array of biochemical targets. More recently, mAbs are being exploited as …
affinity to a diverse array of biochemical targets. More recently, mAbs are being exploited as …